Welcome to our dedicated page for Oncolytics Biotech news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech stock.
Oncolytics Biotech develops pelareorep, an investigational systemically delivered immunotherapy for cancer that has been shown to activate innate immune-sensing pathways. Company news centers on pelareorep clinical and translational data, FDA interactions, and study activity across gastrointestinal and other solid tumor indications, including metastatic colorectal cancer, squamous cell anal carcinoma, pancreatic cancer, and breast cancer.
Recurring updates also cover the company's registration-focused development priorities, Fast Track Designation for pelareorep-based treatment in second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer, scientific meeting presentations, financing arrangements, and its completed change of jurisdiction to Nevada while ONCY common stock continues to trade on Nasdaq.
Oncolytics Biotech Inc. (NASDAQ: ONCY) has announced the upcoming presentation of two significant data sets at the 2025 ASCO Gastrointestinal Cancers Symposium in San Francisco. The presentations will showcase pelareorep's potential in treating gastrointestinal cancers, specifically focusing on pancreatic and anal cancers.
The first abstract (#6) will present preliminary safety and tumor response results for relapsed anal carcinoma patients treated with pelareorep and atezolizumab. The second abstract (#730) will discuss results from the safety run-in for first-line metastatic pancreatic ductal adenocarcinoma patients treated with pelareorep, modified FOLFIRINOX, and atezolizumab.
According to Dr. Tom Heineman, Chief Medical Officer, pelareorep works by engaging patients' immune systems to enhance the effectiveness of chemotherapies and checkpoint inhibitors, potentially improving survival rates in these challenging cancers.
Oncolytics Biotech (NASDAQ: ONCY) announced the completion of initial safety phase enrollment for Cohort 5 of the GOBLET trial in pancreatic cancer. The Data Safety Monitoring Board recommended continued enrollment following review of safety data from six randomized patients. The study will evaluate pelareorep combined with modified FOLFIRINOX, with or without atezolizumab, in newly diagnosed pancreatic ductal adenocarcinoma patients.
The cohort, funded by a $5 million PanCAN Therapeutic Accelerator Award, will initially enroll 30 patients with potential expansion to 64 participants. Safety data is expected in H1 2025, with initial efficacy results in H2 2025.
Oncolytics Biotech (NASDAQ: ONCY) reported Q3 2024 financial results and operational highlights. The company's BRACELET-1 trial showed impressive results in HR+/HER2- metastatic breast cancer, with pelareorep + paclitaxel demonstrating 12.1 months progression-free survival versus 6.4 months for paclitaxel alone. The company reported $19.6 million in cash and cash equivalents, with a net loss of $9.5 million ($0.12 per share) compared to $9.9 million ($0.14 per share) in Q3 2023. R&D expenses increased to $6.8 million from $5.8 million year-over-year, while G&A expenses decreased to $3.1 million from $5.2 million.
Oncolytics Biotech will host a conference call and webcast on Tuesday, November 12, 2024, at 8:30 a.m. ET to discuss its third-quarter 2024 financial results and recent operational highlights. The event will be accessible via North American toll-free number (888) 510-2154 and international number (437) 900-0527. Participants can also join through RapidConnect or access the webcast on the Investor Relations page of Oncolytics' website. The webcast will be archived for three months, with a dial-in replay available for one week at (888) 660-6345 (North America) or (289) 819-1450 (International) using replay code 68336#.
Oncolytics Biotech (NASDAQ: ONCY) announced significant progress in breast and pancreatic cancer treatments. The BRACELET-1 trial in HR+/HER2- breast cancer showed a median progression-free survival (PFS) benefit of 5.7 months for the pelareorep + paclitaxel arm compared to chemotherapy alone. This paves the way for a Phase 2 study aimed at FDA accelerated approval, set to begin in H1 2025, targeting 180 patients with advanced/metastatic breast cancer. Additionally, Oncolytics is advancing gastrointestinal cancer studies, with key milestones expected in 2025. Collaborations with GCAR and PanCAN will support further research in pancreatic cancer, with initial efficacy results from the GOBLET study expected in H2 2025.
Oncolytics Biotech Inc. (NASDAQ: ONCY) reported positive results from its BRACELET-1 Phase 2 study evaluating pelareorep in HR+/HER2- advanced or metastatic breast cancer patients. Key findings include:
1. Median overall survival (OS) not reached in the pelareorep + paclitaxel arm, with over half of patients alive at study end.
2. Estimated median OS of at least 32 months for pelareorep + paclitaxel vs 18 months for paclitaxel alone.
3. Two-year survival rate of 64% for pelareorep + paclitaxel vs 33% for paclitaxel alone.
4. Median progression-free survival (PFS) of 12.1 months for pelareorep + paclitaxel vs 6.4 months for paclitaxel alone.
These results, along with the previous IND-213 study, support the potential of pelareorep-based combination therapy in advanced breast cancer. Oncolytics Biotech is now seeking funding for a registration-enabling study.
Oncolytics Biotech Inc. (NASDAQ: ONCY), a clinical-stage immunotherapy company, has announced its participation in two upcoming investment conferences in September 2024. Chief Financial Officer Kirk Look will attend the H.C. Wainwright 26th Annual Global Investment Conference on September 11, while Chief Medical Officer Tom Heineman, M.D., Ph.D., will participate in the 2024 Cantor Global Healthcare Conference on September 19.
Both executives will engage in fireside chats at their respective events in New York City. The company will also conduct one-on-one investor meetings during these conferences. Webcasts of the presentations will be available on Oncolytics' Investor Relations page and archived for three months.
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapy company focused on oncology, has announced its participation in Canaccord Genuity's 44th Annual Growth Conference. The event will take place from August 13-15, 2024 at the InterContinental Boston Hotel.
Chief Medical Officer Dr. Thomas Heineman will engage in a fireside chat on Tuesday, August 13, 2024, at 8:30 a.m. ET in the Hutchinson Room. The presentation will be accessible via webcast on the company's Investor Relations page.
Additionally, Oncolytics' management team will be available for one-on-one investor meetings during the conference. Interested parties can schedule meetings through the conference website, Canaccord representatives, or by emailing jpatton@oncolytics.ca.
Oncolytics Biotech reported Q2 2024 financial results and operational highlights for its pelareorep immunotherapy program. Key updates include:
- Productive FDA feedback on planned registration trial for HR+/HER2- metastatic breast cancer
- On track to report overall survival results from BRACELET-1 breast cancer study in H2 2024
- Dosed first patient in new GOBLET pancreatic cancer cohort supported by PanCAN funding
- Collaboration with GCAR for adaptive registration-enabling pancreatic cancer trial
Financial highlights:
- Cash position of $24.9 million, providing runway into 2025
- Q2 2024 net loss of $7.3 million vs $7.4 million in Q2 2023
- R&D expenses increased to $4.6 million in Q2 2024 vs $3.7 million in Q2 2023
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapy company focused on oncology, has announced a conference call and webcast scheduled for Thursday, August 1, 2024, at 4:30 p.m. ET. The event will provide a corporate update and discuss financial results for the second quarter of 2024. Investors and interested parties can join via North American toll-free number (800) 836-8184 or international number (646) 357-8785, using conference ID 34386. A webcast will also be available on the company's Investor Relations page and archived for three months. A dial-in replay will be accessible for one week after the call.